

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

WHAT IS CLAIMED IS:

1. A compound of the formula:



a pharmaceutically acceptable salt or a prodrug thereof,

wherein

R¹ is alkyl or -NR⁷R⁸, where each of R⁷ and R⁸ is independently hydrogen or alkyl;

R² is hydrogen or alkyl;

each of R³, R⁴, R⁵, and R⁶ is independently hydrogen, halide, alkyl, -OR⁹ (where R⁹ is hydrogen, alkyl, a hydroxy protecting group, or cycloalkylalkyl), -SR¹⁰ (where R¹⁰ is hydrogen or alkyl), or -NR¹¹R¹² (where each of R¹¹ and R¹² is independently hydrogen, alkyl, or a nitrogen protecting group), provided R³, R⁴, R⁵, and R⁶ are not all simultaneously alkyl); or R³ and R⁴ together with atoms to which they are attached to form heterocyclyl, heteroaryl, or cycloalkyl; and R¹⁴ is hydrogen, lower alkyl or -OR¹⁵, where R¹⁵ is hydrogen, lower alkyl, or a hydroxy protecting group.

2. The compound according to Claim 1, wherein R¹⁴ is hydrogen.

3. The compound according to Claim 2, wherein R¹ is alkyl.

4. The compound according to Claim 3, wherein R¹ is selected from the group consisting of methyl, ethyl, and isopropyl.

5. The compound according to Claim 3, wherein R² is hydrogen.

6. The compound according to Claim 5, wherein each of R⁷ and R⁸ is independently hydrogen or methyl.

1 7. The compound according to Claim 6, wherein each of R³, R⁴, R⁵, and
2 R⁶ is independently hydrogen, halide, alkyl, or -OR⁹, where R⁹ is hydrogen, alkyl, a hydroxy
3 protecting group, or cycloalkylalkyl; or R³ and R⁴ together with atoms to which they are
4 attached to form heterocyclyl, heteroaryl, or cycloalkyl.

1 8. The compound according to Claim 7, wherein at least one of R³, R⁴,
2 R⁵, and R⁶ is alkyl, halide, or -OR⁹, where R⁹ is as defined in Claim 1.

1 9. The compound according to Claim 8, wherein at least one of R³, R⁴,
2 R⁵, and R⁶ is bromo, chloro, fluoro, methoxy, ethoxy, methyl, and hydroxy.


1 10. The compound according to Claim 9, wherein

- 2 (a) R³ is methoxy, and R⁴, R⁵, and R⁶ are hydrogen;
3 (b) R³ is methyl, R⁶ is methoxy, and R⁴ and R⁵ are hydrogen;
4 (c) R³ is methyl, R⁶ is chloro, and R⁴ and R⁵ are hydrogen;
5 (d) R³ is chloro, R⁴ is methoxy, and R⁵ and R⁶ are hydrogen;
6 (e) R³ is methyl, R⁴ is chloro, and R⁵ and R⁶ are hydrogen;
7 (f) R³ is methyl, R⁴ is methoxy, and R⁵ and R⁶ are hydrogen;
8 (g) R⁴ is chloro, and R³, R⁵ and R⁶ are hydrogen;
9 (h) R⁴ is methoxy, and R³, R⁵, and R⁶ are hydrogen.
10 (i) R³ is methyl, R⁶ is bromo, and R⁴ and R⁵ are hydrogen;
11 (j) R³ is bromo, R⁴ is methoxy, and R⁵ and R⁶ are hydrogen;
12 (k) R³ is methyl, R⁴ is bromo, and R⁵ and R⁶ are hydrogen;
13 (l) R⁴ is bromo, and R³, R⁵ and R⁶ are hydrogen; or
14 (m) R³ is ethoxy and R⁴, R⁵ and R⁶ are hydrogen.


1 11. The compound according to Claim 7, wherein R³ and R⁴ together with
2 atoms to which they are attached to form furanyl, dihydrofuranyl, or pyrrolyl.

1 12. The compound according to Claim 11, wherein R³ and R⁴ together
2 with atoms to which they are attached to form furanyl or dihydrofuranyl.


1 13. The compound according to Claim 12, wherein said compound is of
2 the formula:



1 14. A method for producing an imidazolin-2-ylmethyl-substituted aromatic
2 compound of the formula:



4 said method comprising contacting a nitrile compound of the formula:



6 with ethylene diamine to produce the imidazolin-2-ylmethyl-substituted aromatic compound,
7 wherein

8 R¹ is alkyl, -NR⁷R⁸, where each of R⁷ and R⁸ is independently hydrogen or
9 alkyl;

10 R² is hydrogen or alkyl;

11 each of R³, R⁴, R⁵, and R⁶ is independently hydrogen, halide, alkyl, -OR⁹,

12 where R⁹ is hydrogen, alkyl, a hydroxy protecting group, or

13 cycloalkylalkyl, -SR¹⁰, where R¹⁰ is hydrogen or alkyl, or -NR¹¹R¹²,

14 where each of R¹¹ and R¹² is independently hydrogen, alkyl, or a


15 nitrogen protecting group, provided R³, R⁴, R⁵, and R⁶ are not all

16 simultaneously alkyl); or R³ and R⁴ together with atoms to which they


17 are attached to form heterocyclyl, heteroaryl, or cycloalkyl; and

18 R¹⁴ is hydrogen, lower alkyl or -OR¹⁵, where R¹⁵ is hydrogen, lower alkyl, or
19 a hydroxy protecting group.

15. A method for producing an imidazolin-2-ylmethyl-substituted aromatic compound of the formula:



said method comprising contacting an ester compound of the formula:



with ethylene diamine in the presence of a trialkylaluminum to produce the imidazolin-2-ylmethyl-substituted aromatic compound,

wherein

R^1 is alkyl, $-NR^7R^8$, where each of R^7 and R^8 is independently hydrogen or alkyl;

R^2 is hydrogen or alkyl;

each of R^3 , R^4 , R^5 , and R^6 is independently hydrogen, halide, alkyl, $-OR^9$, where R^9 is hydrogen, alkyl, a hydroxy protecting group, or cycloalkylalkyl, $-SR^{10}$, where R^{10} is hydrogen or alkyl, or $-NR^{11}R^{12}$, where each of R^{11} and R^{12} is independently hydrogen, alkyl, or a nitrogen protecting group; or R^3 and R^4 together with atoms to which they are attached to form heterocyclyl, heteroaryl, or cycloalkyl;

R^{13} is alkyl; and

R^{14} is hydrogen, lower alkyl or $-OR^{15}$, where R^{15} is hydrogen, lower alkyl, or a hydroxy protecting group.

16. The method of Claim 15, wherein the trialkylaluminum is trimethylaluminum or triethylaluminum.

17. A composition comprising:

- (a) a therapeutically effective amount of a compound of Claim 1; and
- (b) a pharmaceutically acceptable carrier.

1 18. A method for treating a disease state selected from the groups
2 consisting of urge incontinence, stress incontinence, overflow incontinence, functional
3 incontinence, sexual dysfunction, nasal congestion, and CNS disorders selected from the
4 group depression, anxiety, dementia, senility, Alzheimer's, deficiencies in attentiveness and
5 cognition, eating disorders, obesity, bulimia and anorexia, said method comprising
6 administering to a patient in need of such treatment a therapeutically effective amount of a
7 compound of Claim 1.

1 19. A method for treating a disease state comprising urinary incontinence
2 by administering to a subject in need of such treatment an effective amount of a Compound
3 of Claim 1.
4

1 20. The method of Claim 19, wherein the disorder is stress incontinence.

1 21. The method of Claim 19, wherein the disorder is urge incontinence.

1 22. A method for treating nasal congestion by administering to a mammal
2 in need of such treatment an effective amount of a Compound of Claim 1.

1 23. The method of Claim 22, wherein the disorder is nasal congestion.

1 24. The method of Claim 23, wherein the disorder is sinusitis or otitis.

1 25. A method for treating sexual dysfunction by administering to a
2 mammal in need of such treatment an effective amount of a Compound of Claim 1.